You are here

Pharmaceutical R&D

Drug Interaction with RBC

Drug development often requires obtaining an understanding of potential drug interaction with red blood cells, to ascertain if it could present a hemolytic hazard to patients. While hemolysis testing itself is important, RBC fragility testing can offer more precise characterization of a cell population’s overall effect from a substance. In addition to such uses in preclinical hemocompatibility testing, for certain kinds of pharmaceutical products their potential efficacy is likewise something that RBC mechanical fragility can aid in assessing. 

As an example of Blaze’s technology being applied to study a particular drug, changes in mechanical fragility (MF) of a sickle cell disease (SCD) patient’s blood were analyzed in the presence of a drug aimed at improving rheological properties of RBC.  MF was profiled using a range of shear stressing parameters, including varied fluid flow type – using Blaze’s proprietary means of controlled stress application. It was observed that whether the flow employed in testing was predominantly turbulent or laminar had a major impact on whether the drug appeared to increase or decrease the patient’s RBC fragility – potentially elucidating different respective aspects of the drug’s effects.